

NEXICLON XR - (EQ 0.17MG BASE,EQ 0.26MG BASE ; TABLET,EXTENDED RELEASE)

| | | | |
|------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| Generic Name | CLONIDINE | Innovator | Athena |
| Dosage | EQ 0.17MG BASE,EQ 0.26MG BASE ; TABLET,EXTENDED RELEASE | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | NEXICLON XR is a central alpha-adrenergic agonist indicated for: • Treatment of hypertension. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.